Cost Of New Hepatitis C Drug Out Of Reach For Developing Countries
IRIN: Life-saving hepatitis C drug approved, but cost is high
“Following approvals in the U.S. and Europe this month of a new drug to treat hepatitis C, activists are pushing for the medication to be made available in poor countries, a development reminiscent of the activism that forced down HIV/AIDS drug prices a decade ago in Brazil, South Africa and Thailand…” (12/23).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.